BioCentury
ARTICLE | Clinical News

Resunab: Completed Phase II enrollment

June 27, 2016 7:00 AM UTC

Corbus completed enrollment of about 44 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating oral Resunab for 84 days. Patients will receive a 5 mg dose once daily on days 1-...